has been CE-marked for epilepsy monitoring and diagnosis, mostperformantforthisseizuretype.
following a cumulative 490 day trial (nine patients, up to Most commercially available sensors do not have regulatory
90 days each) demonstrating its safety and feasibility (37). approval for use in epilepsy, and these sensors span an array
Automatically assisted, visual identification of electrographic of form factors and capabilities. The majority of commercial
seizureshasalsobeendemonstratedintheultralong-termsetting smartwatchesnowcarryaccelerometricandPPGsensors,which
(>6months)withthissystem,withexcellentsensitivitybutlow could be useful in tracking seizures (53), and smartwatch